Cataract surgery’s hidden battleground: How OVDs became strategic for Alcon, BLCO and JNJ

Ophthalmic viscoelastic devices, the syringe-loaded gels surgeons inject into the eye to keep the anterior chamber inflated during cataract, glaucoma and corneal procedures, sit inside one of the largest and most consequential consumables markets in modern surgery. Global cataract volumes are rising faster than the supply of trained surgeons, demographics in every developed economy are pushing the elderly cohort sharply higher, and the major OVD producers are now competing on rheology, packaging volume, and bundling strategy rather than price. The category has moved from a quiet adjunct to a strategic asset for Alcon, Bausch + Lomb, Johnson and Johnson Vision and a tightening field of regional challengers.

The total addressable market depends heavily on how the category is defined, and the spread of public estimates is wide enough to be analytically important. A Mordor Intelligence assessment placed the global ophthalmic viscosurgical devices market at roughly USD 460 million in 2025, projecting USD 630 million by 2030 at a compound annual growth rate of 6.5 percent. A Precedence Research estimate published in mid-2025 sized the same category at USD 565 million for 2025 with a USD 806 million projection for 2034. Straits Research valued the segment at USD 476 million for 2025 with USD 738 million by 2033. The wider industry-defined Ophthalmic Viscoelastic Devices market, which absorbs adjacent products and bundled formulations, has been valued by IMARC Group at USD 2.8 billion for 2024 and projected to reach USD 3.8 billion by 2033, while The Business Research Company sized the broader OVD market at USD 2.75 billion for 2025 with USD 3.35 billion expected by 2029.

The variance is not a measurement failure but a category definition problem, and it matters for any investor or sector strategist trying to understand the runway. The narrower viscosurgical-only band reflects the syringe-level consumable. The wider band reflects bundled platforms, dispersive plus cohesive packs, prefilled premium combinations, and adjacent surgical aids. The differential between the two sets of forecasts indicates where the real growth is, namely in bundling and premiumisation rather than in unit-volume expansion alone.

What is driving global demand for ophthalmic viscoelastic devices in cataract surgery and beyond

Cataract is the world’s leading cause of reversible blindness, and the underlying patient pool is expanding faster than surgical capacity in most regions. A peer-reviewed meta-analysis published in Eye, the journal of the Royal College of Ophthalmologists, estimated that 17 million people globally were blind from cataract in 2020 and 83.5 million had moderate to severe visual impairment from the condition, with women making up 60 percent of the cataract-blind cohort. The Global Burden of Disease Study reported cataract as accounting for 45 percent of global blindness in 2020. The World Health Organization has separately estimated global cataract occurrence at 65.2 million cases, the majority concentrated in developing countries.

The downstream effect on viscoelastic device demand is direct and measurable. The United Kingdom’s National Health Service has projected that cataract surgery, already accounting for around 6 percent of total surgeries in England, will increase 25 percent by 2027 and 50 percent by 2035. A 2024 study published through the Cambridge Ophthalmology Symposium noted that the share of NHS cataract surgeries delivered by the independent sector has risen from below 30 percent before the pandemic to roughly 60 percent today, an institutional shift that benefits ambulatory surgical centre supply chains and the prefilled single-use OVD packs they prefer.

A separate Healio analysis of Global Vision Database survey data found that effective cataract surgical coverage globally rose from 28.2 percent to 43.9 percent between 2010 and 2020, but with extreme variance, ranging from 2.1 percent in Burundi to 77.7 percent in Qatar. The world is, by the latest data, not on track to meet the 2030 cataract surgery coverage targets agreed at the World Health Assembly. The implication for OVD demand is structural rather than cyclical. Even if surgical coverage improves at the upper end of forecast trajectories, the unmet demand backlog alone supports rising consumable volumes for at least the next decade.

How are Alcon, Bausch and Lomb and Johnson and Johnson Vision competing in the ophthalmic viscoelastic devices market

The competitive landscape has consolidated around three multinational anchors and a long tail of regional specialists. Alcon, headquartered in Switzerland, retains the legacy strength of the Viscoat and ProVisc franchises and, at its March 2025 Capital Markets Day, signalled fresh investment in next-generation viscoelastic formulations and digital surgery platforms, with two pipeline products flagged for late-2026 launch. Industry trade press characterised the move as a defensive bid to protect Alcon’s viscoadaptive share, particularly against Johnson and Johnson’s Healon family.

Johnson and Johnson Vision pairs its Healon series with the September 2024 expansion of the TECNIS Odyssey presbyopia-correcting intraocular lens portfolio in the United States, with company guidance to use Johnson and Johnson-branded viscoadaptive OVDs alongside the IOL roll-out. The bundling logic is straightforward. As premium IOLs migrate from niche to mainstream, the viscoelastic chosen during implantation becomes a procurement decision linked to the lens itself, not an independent consumable choice.

Bausch and Lomb has moved aggressively on the dual-pack format. The company’s TotalVisc Viscoelastic System, which combines its StableVisc cohesive OVD with the FDA-approved ClearVisc dispersive OVD launched in 2021, was positioned at US debut as the highest fill volume in the dual-pack OVD segment, providing one millilitre each of ClearVisc and StableVisc. The strategic intent is efficiency at the ASC level, eliminating the need to open a second pack mid-procedure and reducing per-case waste. The TotalVisc launch also notably included sorbitol as an oxidative-stress mitigator, a formulation talking point that has begun to shape competitive positioning in the cohesive segment.

A second tier of producers, including Carl Zeiss Meditec, Hoya Corporation, Rumex International, India-based Ophtechnics Unlimited and Neu Micromed, alongside specialists such as Truviz Ophthalmic and Iso Clear, fragments the residual market. The regional players have a meaningful cost advantage in emerging markets but limited regulatory bandwidth to challenge the multinationals in the United States, the European Union, or Japan.

Why are dispersive and cohesive segments showing different growth trajectories within the OVD market

By product type, the segmentation tells a more interesting story than the headline numbers suggest. Precedence Research data assigned the dispersive segment 49 percent revenue share in 2024, while a Mordor Intelligence breakdown placed dispersive agents at 37.6 percent revenue share in the same year, with the variance again reflecting category definition. Both research houses agreed that the viscoadaptive segment, the combination products that toggle behaviour mid-procedure, is the fastest-growing category. This matters competitively because viscoadaptive products carry higher gross margin, lock surgeons into single-vendor procurement, and travel naturally with premium IOL portfolios.

Cohesive products historically dominated by share due to their utility in capsular bag inflation and easier post-surgical removal, while dispersive products gained share through superior endothelial protection. The current generation of dual-action and viscoadaptive products is collapsing that distinction, which is why Alcon, Bausch and Lomb and Johnson and Johnson are all investing R and D capital in formulations that minimise the trade-off rather than choose between sides of it.

What does the regional segmentation reveal about the future of the ophthalmic viscoelastic devices market

North America held the dominant regional share through 2024, with Precedence Research placing the region at 36 percent of global market value and the United States alone accounting for USD 146.7 million in OVD revenue in 2024, projected to reach USD 222.3 million by 2034 at a compound annual growth rate of 4.24 percent. The North American dominance is a function of FDA-approved product availability, ASC density, and reimbursement architecture rather than underlying disease prevalence.

Asia Pacific is the fastest-growing regional market, with India and China carrying outsized weight. South Asia has the highest absolute number of cataract-blind individuals globally and the highest regional prevalence of cataract-related blindness, according to the Global Burden of Disease analysis. The implication is that a meaningful proportion of the next decade’s OVD volume growth will come from price-sensitive markets where local manufacturers like Ophtechnics Unlimited compete directly with multinational brands. Margin compression in these markets is likely to be a persistent feature of the competitive dynamic.

Europe sits in the middle, with capacity constraints rather than demand constraints driving the market. The NHS independent-sector shift in the United Kingdom is the most visible example, but similar pressures exist across Germany, France, Italy and Spain as elective surgical backlogs work through systems with limited theatre capacity.

What are the regulatory, reimbursement and intervention factors shaping OVD market access

Regulatory pathway is the single largest moat protecting incumbent OVD producers. The United States Food and Drug Administration classifies OVDs as Class III medical devices, requiring Premarket Approval rather than 510(k) clearance, a distinction that materially raises the cost and time required for new market entry. The European Union’s Medical Device Regulation framework imposes broadly equivalent rigour. China’s National Medical Products Administration has moved toward harmonisation with international standards but maintains a separate clinical evidence requirement that lengthens local launches.

Reimbursement is the second structural lever. In the United States, OVDs used in cataract surgery are bundled into the facility fee under the Centers for Medicare and Medicaid Services payment system rather than separately reimbursed, which means hospitals and ASCs treat OVDs as cost centres and price-shop aggressively unless surgeons demand specific products. This dynamic has historically suppressed price growth and forced manufacturers to compete on bundling, fill volume, and surgeon preference rather than headline pricing power. In Europe, the picture is more variable, with several national systems treating OVDs as separately reimbursable line items in cataract surgery DRGs.

The intervention picture, finally, is broader than cataract alone. Glaucoma surgery, particularly minimally invasive glaucoma surgery, is the fastest-growing application segment by procedure count, even though it represents a smaller share of OVD revenue than cataract. Corneal grafting, which the Eye Bank Association of America records at over 85,000 tissue distributions annually in the US alone, is a smaller but stable contributor. Vitreoretinal surgery represents an emerging application as device formulations adapt to posterior-segment use cases.

What are the key takeaways from the global ophthalmic viscoelastic devices market analysis

• Global OVD market estimates range from USD 460 million for the narrow viscosurgical category to USD 2.8 billion for the broader OVD definition, with the gap reflecting bundling and platform inclusion rather than measurement error.
• Cataract is the world’s leading cause of reversible blindness with 17 million people blind from the condition and 83.5 million visually impaired in 2020, providing structural demand support for OVD volumes through at least 2035.
• The NHS in England has projected cataract surgery volumes to rise 25 percent by 2027 and 50 percent by 2035, with the independent sector now performing 60 percent of cases versus under 30 percent before the pandemic.
• Alcon, Bausch and Lomb and Johnson and Johnson Vision dominate the multinational tier, with Alcon flagging two pipeline OVD products for late-2026 launch at its March 2025 Capital Markets Day.
• Johnson and Johnson’s TECNIS Odyssey presbyopia-correcting IOL bundling strategy with company-branded viscoadaptive OVDs illustrates how the OVD purchase decision is migrating into premium IOL procurement workflows.
• Bausch and Lomb’s TotalVisc dual-pack with one millilitre of cohesive StableVisc and dispersive ClearVisc plus sorbitol targets ASC efficiency and is the highest fill volume in the US dual-pack segment.
• Viscoadaptive products are the fastest-growing product type, collapsing the historical cohesive versus dispersive trade-off and lifting average selling prices across the category.
• North America held 36 percent of global OVD revenue in 2024, while Asia Pacific is the fastest-growing region, with South Asia carrying the highest absolute cataract-blindness burden globally.
• US OVDs are bundled into CMS facility fees in cataract surgery, suppressing price growth and forcing competition on fill volume, packaging and bundling rather than headline pricing.
• Effective global cataract surgical coverage rose from 28.2 percent to 43.9 percent between 2010 and 2020 but ranges from 2.1 percent in Burundi to 77.7 percent in Qatar, signalling persistent unmet demand and a long structural runway for OVD consumption.